Loading...
Loading...
CEMI| Name | Value |
|---|---|
| Revenues | 11.2M |
| Cost of Revenue | 9.7M |
| Gross Profit | 1.5M |
| Operating Expense | 7.4M |
| Operating I/L | -5.9M |
| Other Income/Expense | -0.8M |
| Interest Income | 0.0M |
| Pretax | -6.7M |
| Income Tax Expense | 1.6M |
| Net Income/Loss | -8.3M |
Chembio Diagnostics, Inc. develops, manufactures, and sells point-of-care diagnostic tests for diseases such as COVID-19, HIV, Syphilis, Zika virus, malaria, dengue, and others. The company's products are sold under various trademarks and distributed to medical laboratories, hospitals, governmental and public health entities, NGOs, medical professionals, and retail establishments globally. Chembio Diagnostics, Inc. generates revenue through direct sales and collaborations with organizations like the Bill & Melinda Gates Foundation, U.S. government agencies, and research foundations, focusing on providing rapid and accurate diagnostic solutions for various infectious diseases.
